Warfarin dosing and the promise of pharmacogenomics

Current Clinical Pharmacology

Volumn 2, Issue 1, 2007, Pages 11-21

  Dumas, Todd E ^a   Hawke, Roy L ^a   Lee, Craig R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CYP2C9; Pharmacogenomics; Polymorphism; VKORC1; Warfarin

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); VITAMIN K DEPENDENT CARBOXYLASE; WARFARIN;

AMINO ACID SUBSTITUTION; ANTICOAGULATION; BLEEDING; COST BENEFIT ANALYSIS; COST CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG COST; DRUG DISPOSITION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THERAPY RESISTANCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 34248159096     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407779422276     Document Type: Review

References (95)

1. Last JA. The missing link: the story of Karl Paul Link. Toxicol Sci 2002; 66: 4-6.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-33S.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
4. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002; 25: 447-54.
5. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-92.
6. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-7.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
9. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-6.
10. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
11. Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care 2004; 10: S58-65.
12. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anti-coagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
13. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
14. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999; 159: 1574-8.
15. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005; 293: 699-706.
16. Coumadin (Warfarin Sodium Tablets, USP) [Product Information]. Princeton, NJ: Bristol-Myers Squibb Company, April 2005.
17. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
18. Mann KG. The challenge of regulating anticoagulant drugs: focus on warfarin. Am Heart J 2005; 149: S36-42.
19. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
20. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
21. Meehan RR, Gosden JR, Rout D, et al. Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988; 42: 26-37.
22. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-99.
23. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-39.
24. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
25. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-8.
26. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9.
27. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-7.
28. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8.
29. Blaisdell J, Jorge-Nebert LF, Coulter S, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527-37.
30. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14: 813-22.
31. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-9.
32. Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-9.
33. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085-90.
34. Veenstra DL, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353-64.
35. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Thromb Haemost 2006; 95: 192-4.
36. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
37. Lee CR. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find Exp Clin Pharmacol 2004; 26: 463-72.
38. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
39. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-52.
40. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
41. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003; 3: 202-14.
42. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
43. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leuvariants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56: 243-51.
44. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999; 35: 253-5.
45. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267: 83-90.
46. Tai G, Farin F, Rieder MJ, et al. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005; 15: 475-81.
47. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
48. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
49. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
50. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-10.
51. Linder MW, Looney S, Adams JE, 3rd, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 227-32.
52. Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-9.
53. Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 2003; 74: 61-8.
54. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
55. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
56. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004; 75: 198-203.
57. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
58. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.
59. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-47.
60. Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002; 108: 221-6.
61. Wajih N, Sane DC, Hutson SM, Wallin R. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem 2005; 280: 10540-7.
62. Sun YM, Jin DY, Camire RM, Stafford DW. Vitamin K epoxide reductase significantly improves carboxylation in a cell line over-expressing factor X. Blood 2005; 106: 3811-5.
63. Cain D, Hutson SM, Wallin R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 1997; 272: 29068-75.
64. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
65. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
66. Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart 2005; 91: 563-4.
67. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
68. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
69. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
70. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-70.
71. Veenstra DL, You JH, Rieder MJ, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-91.
72. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
73. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
74. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
75. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-5.
76. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 2005; 106: 3673-4.
77. Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 365-72.
78. Wallin R, Guenthner TM. Purification of warfarin-sensitive vitamin K epoxide reductase. Methods Enzymol 1997; 282: 395-408.
79. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005; 3: 1873-8.
80. Wallin R, Hutson SM. Warfarin and the Vitamin K-Dependent [gamma]-Carboxylation System. Trends in Molecular Medicine 2004; 10: 299-302.
81. van't Hooft FM, Silveira A, Tornvall P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93: 3432-41.
82. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and interpopulation differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-10.
83. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-8.
84. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817-21.
85. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 23-6.
86. Kohnke H, Sorlin K, Granath G, Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 2005; 61: 381-8.
87. Visser LE, van Schaik RH, van Vliet M, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479-85.
88. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129: 72-8.
89. Estrada CA, Martin-Hryniewicz M, Peek BT, Collins C, Byrd JC. Literacy and numeracy skills and anticoagulation control. Am J Med Sci 2004; 328: 88-93.
90. Lee CR. Warfarin initiation and the potential role of genomic-guided dosing. Clin Med Res 2005; 3: 205-6.
91. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004; 10: S451-58; discussion S8-61.
92. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004; 10: 425-32.
93. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005; 573: 180-94.
94. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3: 137-45.
95. Summary Minutes of the Clinical Pharmacology Subcommittee Meeting of the Advisory Committee for Pharmaceutical Science. Rockville, MD: Center for Drug Evaluation and Research Advisory Committee; November 14-15, 2005.